HC Wainwright & Co. Maintains Buy on FibroBiologics, Lowers Price Target to $6

Benzinga Newsdesk www.benzinga.com Negative 50.0%

Neg 50% Neu 0% Pos 0%

HC Wainwright & Co. analyst Matthew Caufield maintains FibroBiologics (NASDAQ:FBLG) with a Buy and lowers the price target from $8 to $6.